MHRA explains obligations under EU regulation & accreditation proposal
This article was originally published in RAJ Devices
The UK Medicines and Healthcare products Regulatory Agency has published a document explaining how it intends to fulfil its obligations under the revised European Union framework on the free movement of goods, including medical devices1.
You may also be interested in...
After EU regulators decided that biological medicines should be reviewed for the presence of possible nitrosamine impurities – as is already required for chemical medicines – new deadlines have been agreed on to give companies enough time to comply.
The UK Medicines and Healthcare products Regulatory Agency has issued updated guidance and application form to help clinical trial sponsors provide better information on reports of serious breaches, which in turn would support the agency in assessing the issue.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.